Literature DB >> 30267627

The rational specimen for the quantitative detection of Epstein-Barr virus DNA load.

Wang Kedi1, Xu Dongjiang2, Lv Zhi1, Gao Yan1, Jia Kun1, Su Jianrong3.   

Abstract

Background Epstein-Barr virus (EBV) DNA load monitoring in blood is essential for the diagnosis of EBV-associated diseases. However, the best-suited blood compartment for detection is still under discussion. The aim of this study was to evaluate the diagnostic value of EBV-DNA load in peripheral blood mononuclear cells (PBMC), plasma and whole blood (WB) samples. Methods A total of 156 patients, including 45 patients with infectious mononucleosis (IM), 57 patients with EBV-associated hemophagocytic lymphohistiocytosis (HLH) and 54 patients with post-transplant lymphoproliferative disorders (PTLD), were enrolled in this study. The EBV-DNA load in PBMC, plasma and WB samples were measured with real-time quantitative polymerase chain reaction (PCR). Results EBV-DNA load of patients with HLH showed no statistical difference in PBMC, plasma and WB samples, while patients with IM and PTLD showed a higher viral load in PBMC samples. The strongest correlation of EBV-DNA level was found between PBMC and WB samples among patients with IM, HLH and PTLD. The follow-up of EBV-DNA showed that the viral load became negative along with the recovery from the disease, while that in WB and PBMC would remain positive for a long time. Conclusions For the diagnosis and monitoring of EBV-DNA, the type of specimen should be chosen reasonably according to the disease. As for IM and HLH, plasma is recommended to quantify the EBV-DNA load, while PBMC and plasma are preferred in PTLD.

Entities:  

Keywords:  DNA; Epstein-Barr virus; peripheral blood mononuclear cells; plasma; whole blood

Year:  2019        PMID: 30267627     DOI: 10.1515/cclm-2018-0733

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  1 in total

1.  Epstein-Barr virus seroprevalence and viral load at disease onset in children with inflammatory bowel disease.

Authors:  Gaël Kornitzer; Michelle Rosenstein; Marie-Catherine Turcotte; David Godin; Véronique Groleau; Christian Renaud; Fabien Touzot; Prevost Jantchou; Philippe Ovetchkine; Colette Deslandres
Journal:  JGH Open       Date:  2022-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.